רווח למניה בשנים עשר החודשים האחרונים: Genprex Inc. (GNPX)

Genprex, Inc. (GNPX) possesses significant market influence due to the ONCOPREX system, which delivers tumor suppressor genes into tumors. Laboratory automation via robotic screening accelerates preclinical development. GURU.Markets analytics show a change in the rolling annual EPS, where -157.38 represents the latest level value. Stable demand for oncology therapies positions the asset beyond economic cycles, tying success to FDA verdicts.

Trailing twelve months (TTM) earnings per share reflects the portion of profit attributable to a single common share. Investors utilize this indicator to assess real capital generation efficiency and business growth rates. By analyzing the rolling annual earnings per share, one can determine the stability of the issuer's margins. For Genprex, Inc. (GNPX), this metric is critical, as the development of the ONCOPREX system requires colossal expenditures. Positive dynamics would confirm the commercial success of the lung cancer therapy.